Security
BioMarin Pharmaceutical Inc. Common Stock · BMRN
BMRNNASDAQCommon stockCurrentCIK 1048477Updated Oct 7, 2026
BMRN price & chart
Loading TradingView…
NASDAQ:BMRN on TradingView ↗About the company
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
In the news
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility News provided by BioMarin Pharmaceutical Inc. Jan 29, 2026, 16:05 ET Share this article Share to X Share this article Share to X SAN RAFAEL, Calif. , Jan. 29, 2026 /P ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02
Entry into a Material Definitive Agreement
Items 1.01
Other Events
Items 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
144 filing
Show 5 more recent filings
Other Events
Items 8.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
S-8 filing
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,614,868,000Source | 6,851,195,000Source | 11,723,442,000Source | 7,456,341,000Source | 7,067,121,000Source | 8,591,016,000Source | 7,147,007,000Source | 6,872,673,000Source | 7,594,022,000Source | 6,988,940,000Source | 6,841,603,000Source | 6,375,074,000Source |
| Property, Plant and Equipment, NetUSD | 1,038,187,000Source | 1,045,408,000Source | 989,994,000Source | 1,030,385,000Source | 1,052,898,000Source | 958,071,000Source | 1,032,613,000Source | 1,060,425,000Source | 952,508,000Source | 1,043,041,000Source | 1,066,133,000Source | 1,073,366,000Source |
| GoodwillUSD | 196,199,000Source | 196,199,000Source | 655,745,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 233,112,000Source | 260,920,000Source | 4,879,367,000Source | 239,620,000Source | 265,533,000Source | 204,662,000Source | 247,346,000Source | 279,653,000Source | 213,837,000Source | 255,278,000Source | 294,701,000Source | 338,569,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,250,108,000Source | 675,448,000Source | 874,005,000Source | 1,213,816,000Source | 972,150,000Source | 2,222,435,000Source | 1,048,803,000Source | 746,996,000Source | 1,311,679,000Source | 942,842,000Source | 755,127,000Source | 724,531,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 790,266,000Source | 777,547,000Source | 1,061,047,000Source | 855,855,000Source | 691,232,000Source | 903,914,000Source | 739,177,000Source | 637,163,000Source | 908,214,000Source | 660,535,000Source | 633,704,000Source | 461,316,000Source |
| Inventory, NetUSD | 1,382,173,000Source | 1,179,339,000Source | 1,782,524,000Source | 1,340,169,000Source | 1,183,621,000Source | 1,273,221,000Source | 1,274,848,000Source | 1,137,982,000Source | 1,298,883,000Source | 1,232,653,000Source | 1,107,183,000Source | 894,083,000Source |
| Assets, CurrentUSD | 3,854,543,000Source | 3,056,590,000Source | 3,971,623,000Source | 3,805,332,000Source | 3,259,630,000Source | 4,605,070,000Source | 3,467,905,000Source | 2,985,012,000Source | 3,953,490,000Source | 3,232,427,000Source | 2,956,088,000Source | 2,751,457,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 35,243,000Source | 28,680,000Source | 42,731,000Source | 34,935,000Source |
| Other Assets, NoncurrentUSD | 270,781,000Source | 199,314,000Source | 338,138,000Source | 249,192,000Source | 190,772,000Source | 276,416,000Source | 235,654,000Source | 184,790,000Source | 277,049,000Source | 251,391,000Source | 171,538,000Source | 176,236,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,558,157,000Source | 1,437,799,000Source | 5,401,750,000Source | 1,429,228,000Source | 1,780,822,000Source | 2,378,909,000Source | 1,353,548,000Source | 1,798,857,000Source | 1,507,023,000Source | 1,330,950,000Source | 1,890,054,000Source | 1,771,918,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 192,000Source | 191,000Source | 194,000Source | 192,000Source | 190,000Source | 193,000Source | 192,000Source | 190,000Source | 192,000Source | 191,000Source | 189,000Source | 186,000Source |
| Retained Earnings (Accumulated Deficit)USD | 200,779,000Source | -319,638,000Source | 304,495,000Source | 231,523,000Source | -425,718,000Source | 259,733,000Source | -9,009,000Source | -532,892,000Source | 154,206,000Source | -194,695,000Source | -621,554,000Source | -789,199,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -33,937,000Source | 4,650,000Source | -8,783,000Source | -44,565,000Source | 26,799,000Source | -4,237,000Source | 19,151,000Source | -1,046,000Source | -13,473,000Source | 61,653,000Source | -28,788,000Source | -3,867,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,056,711,000Source | 5,413,396,000Source | 6,321,692,000Source | 6,027,113,000Source | 5,286,299,000Source | 6,212,107,000Source | 5,793,459,000Source | 5,073,816,000Source | 6,086,999,000Source | 5,657,990,000Source | 4,951,549,000Source | 4,603,156,000Source |
| Additional Paid in Capital, Common StockUSD | 5,900,968,000Source | 5,739,910,000Source | 6,037,019,000Source | 5,851,637,000Source | 5,696,701,000Source | 5,966,868,000Source | 5,794,302,000Source | 5,619,264,000Source | 5,956,582,000Source | 5,802,068,000Source | 5,611,562,000Source | 5,404,895,000Source |
| Liabilities and EquityUSD | 7,614,868,000Source | 6,851,195,000Source | 11,723,442,000Source | 7,456,341,000Source | 7,067,121,000Source | 8,591,016,000Source | 7,147,007,000Source | 6,872,673,000Source | 7,594,022,000Source | 6,988,940,000Source | 6,841,603,000Source | 6,375,074,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 798,438,000Source | 715,658,000Source | 1,663,996,000Source | 684,247,000Source | 1,067,337,000Source | 793,152,000Source | 628,213,000Source | 1,087,900,000Source | 759,031,000Source | 606,988,000Source | 1,177,024,000Source | 588,884,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 8,569,000Source | 7,233,000Source | 8,640,000Source | 8,088,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | 36,576,000Source | 30,501,000Source | 38,047,000Source | 26,329,000Source |
| Other Liabilities, NoncurrentUSD | 163,056,000Source | 127,514,000Source | 209,815,000Source | 148,819,000Source | 119,369,000Source | 155,475,000Source | 129,685,000Source | 117,352,000Source | 150,816,000Source | 128,824,000Source | 119,935,000Source | 100,015,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 33,276,000Source | 62,559,000Source | 69,205,000Source | 66,127,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Long-term Debt, Current Maturities | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 16,411,000Source | 22,069,000Source | 79,557,000Source | 96,426,000Source | 104,386,000Source | 101,969,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 43,458,000Source | 37,700,000Source | 181,409,000Source | 201,571,000Source | 207,099,000Source | 196,308,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 7,159,000Source | 57,590,000Source | 228,054,000Source | 57,909,000Source | 190,435,000Source | 82,033,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -44,490,000Source | 24,335,000Source | 116,929,000Source | 63,530,000Source | 157,058,000Source | 68,264,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 9,220,000Source | 28,429,000Source | 48,738,000Source | 56,096,000Source | -44,981,000Source | -52,087,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 220,651,000Source | 174,394,000Source | 827,994,000Source | 572,841,000Source | 159,259,000Source | 175,902,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 725,528,000Source | -28,238,000Source | -414,242,000Source | 136,491,000Source | -111,244,000Source | -20,029,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | -4,966,000Source | 0Source | 0Source | -1,141,000Source | 0Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 20,923,000Source | 16,768,000Source | 103,038,000Source | 85,424,000Source | 96,691,000Source | 120,959,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 28,180,000Source | 38,779,000Source | 55,965,000Source | 77,560,000Source | 76,319,000Source | 54,283,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 813,167,000Source | -38,779,000Source | -42,394,000Source | -526,447,000Source | -18,727,000Source | -18,650,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | -889,000Source | -3,177,000Source | 0Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,760,756,000Source | 105,961,000Source | 368,837,000Source | 187,715,000Source | 30,596,000Source | 137,255,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,250,108,000Source | 675,448,000Source | 874,005,000Source | 1,213,816,000Source | 3,072,435,000Source | 1,048,803,000Source | 1,311,679,000Source | 942,842,000Source | 755,127,000Source | 724,531,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 7,245,000Source | 10,361,000Source | 10,303,000Source | 10,281,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 96,205,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 49,265,000Source | 43,489,000Source | 75,695,000Source | 47,531,000Source | 43,458,000Source | 37,700,000Source | 181,409,000Source | 201,571,000Source | 207,099,000Source | 196,308,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 6,086,000Source | 660,000Source | 2,622,000Source | 3,359,000Source | 4,188,000Source | 4,117,000Source |
| Amortization of Intangible AssetsUSD | — | — | 4,847,000Source | 5,009,000Source | 73,492,000Source | 4,846,000Source | 4,483,000Source | 4,847,000Source | 19,386,000Source | 43,257,000Source | — | — |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | 7,400,000Source | — | — | — |
| DepreciationUSD | — | — | 10,600,000Source | 10,900,000Source | 9,600,000Source | 10,600,000Source | 8,800,000Source | 14,100,000Source | 48,500,000Source | 46,600,000Source | 40,300,000Source | 38,600,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | — | — | — | — | — | — | — | 12,600,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -6,100,000Source | -8,600,000Source | -27,700,000Source | -11,400,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -6,710,000Source | 10,026,000Source | -4,459,000Source | 16,753,000Source | -28,446,000Source | 14,287,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 10,000,000Source | 0Source | 108,000,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 108,000,000Source |
| GoodwillUSD | — | — | 196,199,000Source | 196,199,000Source | 655,745,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source | 196,199,000Source |
| Income Tax Expense (Benefit)USD | — | — | 4,420,000Source | 28,361,000Source | 16,622,000Source | 57,336,000Source | 35,676,000Source | 52,403,000Source | 133,579,000Source | 114,904,000Source | 20,918,000Source | 8,015,000Source |
| InterestExpenseNonoperatingUSD | — | — | 2,579,000Source | 2,968,000Source | 63,295,000Source | 2,679,000Source | 14,958,000Source | 2,863,000Source | 10,899,000Source | 12,666,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 119,208,000Source | — | — | 0Source |
| Investment Income, InterestUSD | — | — | 17,854,000Source | 18,053,000Source | 10,480,000Source | 18,827,000Source | 22,560,000Source | 19,013,000Source | 74,904,000Source | 74,883,000Source | 58,339,000Source | 18,034,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,744,000Source | 106,080,000Source | 44,762,000Source | 240,532,000Source | 105,527,000Source | 185,686,000Source | 348,901,000Source | 426,859,000Source | 167,645,000Source | 141,561,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -30,744,000Source | 106,080,000Source | 44,762,000Source | 240,532,000Source | 105,527,000Source | 185,686,000Source | 348,901,000Source | 426,859,000Source | — | 141,561,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 5,093,000Source | 5,463,000Source | 3,279,000Source | 4,833,000Source | 3,961,000Source | -1,954,000Source | 8,997,000Source | -4,668,000Source | -10,538,000Source | -2,050,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 25,792,000Source | 89,274,000Source | 355,875,000Source | 410,250,000Source | 868,496,000Source | 611,809,000Source |
| Amortization of Debt Issuance Costs | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 776,133,000Source | 745,740,000Source | 989,708,000Source | 825,410,000Source | 766,208,000Source | 745,145,000Source | 3,221,253,000Source | 2,853,915,000Source | 2,419,226,000Source | 2,096,039,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 268,415,000Source | 253,480,000Source | 395,549,000Source | 232,279,000Source | 258,290,000Source | 206,116,000Source | 1,153,017,000Source | 1,009,025,000Source | 937,291,000Source | 854,009,000Source |
| Operating Income (Loss)USD | — | — | -46,692,000Source | 113,893,000Source | 110,920,000Source | 276,887,000Source | 129,640,000Source | 223,893,000Source | 409,478,000Source | 484,214,000Source | 158,097,000Source | 149,562,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -26,324,000Source | 134,441,000Source | 61,384,000Source | 297,868,000Source | 141,203,000Source | 238,089,000Source | 482,480,000Source | 541,763,000Source | 188,563,000Source | 149,576,000Source |
| Income Tax Expense (Benefit)USD | — | — | 4,420,000Source | 28,361,000Source | 16,622,000Source | 57,336,000Source | 35,676,000Source | 52,403,000Source | 133,579,000Source | 114,904,000Source | 20,918,000Source | 8,015,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -30,744,000Source | 106,080,000Source | 44,762,000Source | 240,532,000Source | 105,527,000Source | 185,686,000Source | 348,901,000Source | 426,859,000Source | 167,645,000Source | 141,561,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | 0.56Source | 0.23Source | 1.25Source | 0.55Source | 0.97Source | 1.82Source | 2.25Source | 0.89Source | 0.76Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | 0.55Source | 0.23Source | 1.23Source | 0.54Source | 0.95Source | 1.8Source | 2.21Source | 0.87Source | 0.75Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 192,032,000Source | 190,429,000Source | 193,423,000Source | 191,907,000Source | 192,497,000Source | 190,967,000Source | 191,787,000Source | 190,027,000Source | 187,834,000Source | 185,266,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 192,032,000Source | 197,147,000Source | 194,467,000Source | 197,091,000Source | 197,671,000Source | 196,474,000Source | 197,394,000Source | 196,708,000Source | 191,595,000Source | 188,963,000Source |
| Interest Expense (non-operating)USD | — | — | 2,579,000Source | 2,968,000Source | 63,295,000Source | 2,679,000Source | 14,958,000Source | 2,863,000Source | 10,899,000Source | 12,666,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 4,847,000Source | 5,009,000Source | 73,492,000Source | 4,846,000Source | 4,483,000Source | 4,847,000Source | 19,386,000Source | 43,257,000Source | — | — |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | 7,400,000Source | — | — | — |
| Costs and ExpensesUSD | — | — | 822,825,000Source | 631,847,000Source | 878,788,000Source | 548,523,000Source | 636,568,000Source | 521,252,000Source | 2,811,775,000Source | 2,369,701,000Source | 2,261,129,000Source | 1,946,477,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 84,841,000Source | 58,808,000Source | 65,899,000Source | 60,102,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | — | — | — | — | — | — | — | 12,600,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -6,100,000Source | -8,600,000Source | -27,700,000Source | -11,400,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -262,617,000Source | 130,503,000Source | -453,840,000Source | -299,403,000Source |
| Interest ExpenseUSD | — | — | — | — | 60,728,000Source | 2,387,000Source | 9,571,000Source | 2,387,000Source | — | — | 17,335,000Source | 15,970,000Source |
| Investment Income, InterestUSD | — | — | 17,854,000Source | 18,053,000Source | 10,480,000Source | 18,827,000Source | 22,560,000Source | 19,013,000Source | 74,904,000Source | 74,883,000Source | 58,339,000Source | 18,034,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -30,744,000Source | 106,080,000Source | 44,762,000Source | 240,532,000Source | 105,527,000Source | 185,686,000Source | 348,901,000Source | 426,859,000Source | — | 141,561,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 5,093,000Source | 5,463,000Source | 3,279,000Source | 4,833,000Source | 3,961,000Source | -1,954,000Source | 8,997,000Source | -4,668,000Source | -10,538,000Source | -2,050,000Source |
| Reclassification from AOCI, Current Period, before Tax, Attributable to ParentUSD | — | — | -8,139,000Source | 3,537,000Source | -4,055,000Source | -549,000Source | -8,811,000Source | 9,939,000Source | -15,474,000Source | 14,872,000Source | 164,000Source | 36,624,000Source |
| Research and Development ExpenseUSD | — | — | 409,478,000Source | 184,901,000Source | 206,952,000Source | 161,308,000Source | 178,796,000Source | 158,731,000Source | 921,930,000Source | 747,184,000Source | 746,773,000Source | 649,606,000Source |
Filing attachments
d110137dex991.htm · 8-K · 2026-08-31
EX-99.1 2 d110137dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts: Investors Media Traci McCarty Andrew Villani BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (628) 269-7393 BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea Agreement Resolves all Pending Patent-Related Proceedings B…
Read attachment ↗d172628dex991.htm · 8-K · 2026-08-18
EX-99.1 3 d172628dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts: Investors Media Traci McCarty Erin Rau BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (925) 683-9622 BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin’s Pipeline BioMarin to pay $275 million upfront, plus addit…
Read attachment ↗earningsrelease-6aug26ex991.htm · 8-K · 2026-08-06
EX-99.1 2 earningsrelease-6aug26ex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Second Quarter 2026 Financial and Operating Results Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidan…
Read attachment ↗ex991-amicusauditedfinanci.htm · 8-K/A · 2026-07-13
EX-99.1 3 ex991-amicusauditedfinanci.htm EX-99.1 - UNAUDITED FINANCIAL STATEMENTS Document Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Amicus Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Amicus Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, changes in…
Read attachment ↗ex992-unauditedproformafin.htm · 8-K/A · 2026-07-13
EX-99.2 4 ex992-unauditedproformafin.htm EX-99.2 - PRO FORMA FINANCIAL STATEMENTS Document EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 27, 2026, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) completed its previously announced acquisition of all of the issued and outstanding shares of capital stock of Amicus Therapeutics, Inc. (“Amicus”) (the “Merger”). The Merger was completed pursuant to an Agreement and Plan of Merger (the “Agreement”)…
Read attachment ↗earningsrelease-4may26ex991.htm · 8-K · 2026-05-04
EX-99.1 2 earningsrelease-4may26ex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2026 Financial and Operating Results First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to betwe…
Read attachment ↗